CFTR functions as a tumor suppressor in adenoid cystic carcinoma and its silencing reveals an associated vulnerability involving the Hsp70 chaperone system - Scorecard - MDSpire
Advertisement
CFTR functions as a tumor suppressor in adenoid cystic carcinoma and its silencing reveals an associated vulnerability involving the Hsp70 chaperone system
Clinical Scorecard: CFTR Acts as a Tumor Suppressor in Adenoid Cystic Carcinoma, with Its Inhibition Uncovering a Vulnerability Related to the Hsp70 Chaperone System
At a Glance
Category
Detail
Condition
Adenoid Cystic Carcinoma
Key Mechanisms
CFTR downregulation, Hsp70 chaperone system involvement
Target Population
Patients with adenoid cystic carcinoma
Care Setting
Oncology research and treatment
Key Highlights
CFTR is consistently downregulated in adenoid cystic carcinoma.
Low CFTR expression correlates with inferior overall survival.
CFTR acts as a tumor suppressor, inhibiting cell proliferation and invasion.
Hsp70 inhibition mimics the effects of CFTR restoration.
Targeting Hsp70 presents a potential therapeutic strategy.
Guideline-Based Recommendations
Diagnosis
Differential expression analysis of CFTR in tumor samples.
Management
Consider pharmacological inhibition of Hsp70 in treatment strategies.
Monitoring & Follow-up
Evaluate CFTR expression levels as a prognostic marker.
Risks
Increased tumor growth associated with CFTR knockdown.
Patient & Prescribing Data
Individuals diagnosed with adenoid cystic carcinoma.
Pharmacological targeting of Hsp70 may provide therapeutic benefits.
Clinical Best Practices
Monitor CFTR expression in patients for prognostic assessment.
Explore Hsp70 inhibitors in clinical trials for ACC.
